Bisphosphonates in breast cancer

German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer

(2013) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial

(2013) Peter Barrett-Lee et al.   LANCET ONCOLOGY

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

(2012) R. Coleman et al.   ANNALS OF ONCOLOGY

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial

(2012) Alexander HG Paterson et al.   LANCET ONCOLOGY

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

(2011) F. Saad et al.   ANNALS OF ONCOLOGY

Final 5-year results of Z-FAST trial

(2011) Adam M. Brufsky et al.   CANCER

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial

(2011) Antonio Llombart et al.   Clinical Breast Cancer

Bone Targeted Therapies in Early Breast Cancer

(2011) Keo Tabane et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer

(2011) Catherine H. Van Poznak et al.   JOURNAL OF CLINICAL ONCOLOGY

Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis

(2011) Eitan Amir et al.   JNCI-Journal of the National Cancer Institute

Adjuvant bisphosphonates for early-stage breast cancer

(2011) Adam Brufsky   LANCET ONCOLOGY

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

(2011) Michael Gnant et al.   LANCET ONCOLOGY

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

(2011) Robert E. Coleman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial

(2010) Catherine Van Poznak et al.   JOURNAL OF CLINICAL ONCOLOGY

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

(2009) Stephanie L. Hines et al.   BREAST CANCER RESEARCH AND TREATMENT

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Practical guidance for the management of aromatase inhibitor-associated bone loss

(2008) P. Hadji et al.   ANNALS OF ONCOLOGY

Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

(2008) J. E. Lester et al.   CLINICAL CANCER RESEARCH

Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

(2008) Susan L. Greenspan et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

(2008) Michael Gnant et al.   LANCET ONCOLOGY

Cancer Treatment-Induced Bone Loss: Pathophysiology and Clinical Perspectives

(2008) A. M. Brufsky   ONCOLOGIST

Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors

(2008) Adam M. Brufsky   Current Oncology Reports